Melasma vs. post-inflammatory hyperpigmentation
Two different conditions, two different playbooks, one very confused skincare aisle.
Disclosure
Nothing here is sponsored and we earn nothing from anything mentioned. If that ever changes, this box will say so before you read a word of the article.
Evidence at a glance
- Melasma vs PIH
- A Different triggers and different natural histories, distinguishable by pattern and behaviour over months, not by colour alone.
- PIH often fades alone
- A Once its trigger is gone, post-inflammatory pigmentation typically lightens on its own over months, even untreated.
- Melasma needs upkeep
- B Because melasma relapses by nature, dermatology consensus builds a maintenance phase into treatment from day one.
- Treatment can backfire
- A A skin-of-colour-specific review found that cooling devices meant to calm post-procedure skin actually raised PIH risk roughly 2.6-fold.
- Trials skew lighter
- C A 2025 audit of registered melasma trials found Black participants made up under 15% of enrolment despite the disease's skew toward darker skin.
Type "dark patches" into any Indian skincare forum and you'll get two completely different diagnoses thrown back at you as if they're interchangeable: melasma and post-inflammatory hyperpigmentation (PIH). They can look almost identical in a phone photo — brownish, patchy, worse on the cheeks — which is exactly why so much advice treats them as one condition with two names. They are not. They have different causes, different natural histories, and in some cases directly opposite treatment logic, which means "just use vitamin C and stay out of the sun" can help one and do close to nothing for the other.
Two different processes wearing the same disguise
Melasma is, at bottom, a disorder of melanocytes that have become chronically overactive rather than a case of the skin simply making a bit more pigment. Hormonal signalling (oestrogen, pregnancy, some contraceptives), chronic UV and visible-light exposure, and a documented vascular component — more blood vessels and leakier capillaries under the pigmented patches, which appears to feed the pigment-making machinery above it — combine in genetically predisposed skin to keep melanocytes switched on . It tends to show up symmetrically across the cheeks, forehead or upper lip, builds slowly, and — this is the part that trips people up — does not reliably fade on its own once the trigger, say a pregnancy, is gone. Dermatology reviews are blunt about this: melasma is characteristically chronic and relapsing, and unlike PIH, spontaneous resolution "usually does not" happen .
PIH is a different animal: melanocytes reacting to a specific insult — an acne cyst, an eczema flare, a cut, a wax burn, a peel that went too deep — by dumping extra pigment into the surrounding skin as part of the inflammatory clean-up. It follows the shape of whatever caused it (a PIH mark from a popped pimple is a spot; melasma isn't spot-shaped), and critically, once the original trigger is gone, PIH generally fades on its own over months, even with no treatment at all .
Melasma is a light switch that got rewired to stay half-on. PIH is a bruise that happens to be brown.
Why the mix-up isn't harmless
Treat PIH like it's melasma and you'll probably overtreat a mark that was going to fade anyway, sometimes into something worse. This is the trap worth naming directly: an intervention chosen to fix hyperpigmentation can itself be the thing that inflames the skin and produces more of it. A 2025 systematic review specifically on preventing PIH in skin of colour found this in blunt numbers — cooling devices used after procedures, intended to calm the skin, instead came with roughly 2.6 times the risk of PIH compared with not using them, while plain sunscreen, with or without an anti-inflammatory add-on, prevented it in the large majority of cases . The lesson generalises: a peel, laser or acid strong enough to genuinely irritate darker skin doesn't just risk not working — it risks manufacturing a fresh patch of exactly the problem it was booked to solve.
Melasma runs on the opposite logic. Because it relapses by nature rather than by bad luck, dermatology consensus specifically builds a maintenance phase into treatment from day one rather than treating it as a problem you clear and walk away from . None of this requires re-deriving ingredient evidence from scratch — Stratum already grades hydroquinone, azelaic acid, tranexamic acid, niacinamide, alpha arbutin, kojic acid, thiamidol, cysteamine and tinted iron-oxide sunscreen on our pigmentation & melasma hub — what changes between the two conditions is less which actives you reach for and more how aggressively you use them, and whether you plan for a taper-and-maintain regimen (melasma) or a fade-it-out-gently one (PIH).
Both run heavier in darker skin — most trial data doesn't
Melasma and PIH both disproportionately affect people with Fitzpatrick skin types III through VI, which covers most of the Indian population, and both respond to visible light and not just UV — a detail plain SPF numbers say nothing about . That makes the evidence gap sting more than it would elsewhere: a 2025 audit of registered melasma clinical trials found Fitzpatrick types III–IV made up over 75% of enrolled participants, women over 96%, and Black participants under 15% — meaning the skin most affected by the condition is still the skin least represented in the studies used to justify its treatments . Treat every trial result on a pigmentation active as provisional until you've checked, ingredient by ingredient, whether darker skin was actually in the room.
A rough way to tell them apart at home
- Shape and location. Symmetric patches across both cheeks, forehead, nose bridge or upper lip lean melasma. A mark that traces the outline of a specific old spot, cut or rash leans PIH.
- A story behind it. Can you point to the exact injury or breakout that came before it? PIH usually has an origin story. Melasma usually doesn't — it just gradually appeared or darkened, often around a hormonal shift or a summer of sun.
- Behaviour over months, untreated. A mark that's visibly faded on its own after two to three months is more consistent with PIH. One that's stable, spreading, or that keeps coming back in the same spots each summer is more consistent with melasma.
- Response pattern. Melasma tends to partially respond and then plateau or relapse; PIH, once its trigger is controlled, tends to keep improving until it's gone.
None of this replaces an actual diagnosis. The two aren't mutually exclusive — plenty of people have melasma and PIH sitting on the same face, sometimes overlapping — and anything atypical (asymmetric, rapidly changing, unusually dark, resistant to months of sensible care, or turning up somewhere unexpected like a scar or a new mole) is a reason to see a dermatologist rather than keep guessing from a mirror.
The short version
Melasma is a chronic, relapsing overactivity of melanocytes driven by hormones, UV and visible light, with a real vascular component underneath it, and it needs a maintenance plan built in from the start. PIH is a temporary, localised reaction to a specific injury that generally fades without any treatment at all, and the fastest way to make it worse is to treat it with something aggressive enough to irritate the skin all over again. Both hit medium-to-deep skin tones hardest, and the clinical trials behind most of the treatments for both still don't reflect that. When in doubt about which one is on your face, a dermatologist's job is easier than yours — let them look.
This is general education, not medical advice. Nothing here accounts for your history, your medication or your skin, and none of it replaces assessment by a qualified clinician. Where we describe what research found, that is a description of a study — not a promise about you.
References
- Espósito ACC, Cassiano DP, da Silva CN, et al. Update on Melasma—Part I: Pathogenesis Dermatology and Therapy, 2022.PubMed 35904706DOI 10.1007/s13555-022-00779-x
- Masub N, Nguyen JK, Austin E, Jagdeo J The Vascular Component of Melasma: A Systematic Review of Laboratory, Diagnostic, and Therapeutic Evidence Dermatologic Surgery, 2020.PubMed 33252894DOI 10.1097/DSS.0000000000002770
- Maghfour J, Olayinka J, Hamzavi IH, Mohammad TF A Focused review on the pathophysiology of post-inflammatory hyperpigmentation Pigment Cell & Melanoma Research, 2022.PubMed 35306737
- Desai SR, Alexis AF, Elbuluk N, et al. Best practices in the treatment of melasma with a focus on patients with skin of color Journal of the American Academy of Dermatology, 2023.PubMed 37748556
- Wang JY, Zafar K, Bitterman D, et al. Gender, Racial, and Fitzpatrick Skin Type Representation in Melasma Clinical Trials Journal of Drugs in Dermatology, 2025.PubMed 39761136
- Mar K, Khalid B, Maazi M, et al. Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review Australasian Journal of Dermatology, 2025.PubMed 39953770
Related condition hub
Your turn
Did this hold up? Tell us honestly — especially if it didn’t.